Corcept Therapeutics Incorporated CORT recently announced the submission of a new drug application (NDA) to the FDA for its ...

Agents that directly lower ACTH secretion by a pituitary adenoma represent an attractive option for the treatment of Cushing's disease, as these drugs directly target the pathogenesis of disease.

Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the body ...

The US FDA has approved a new orphan drug to treat patients with Cushing’s disease who cannot be helped through surgery. Novartis’ Signifor (pasireotide diaspartate) injection has been ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The drug has received orphan drug designation in the United States and the European Union for the treatment of Cushing's syndrome. Cushing's syndrome is a condition characterized by excessive ...

CORT’s sole marketed drug, Korlym (mifepristone), is already approved for treating Cushing's syndrome. The drug has been witnessing a strong demand in the past couple of quarters and the trend ...

radiotherapy or drug therapy. While medical therapy for Cushing's syndrome has been limited, several new agents are being investigated. This aim of this review is to analyze and present the ...

Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the ...